By Stephen Nakrosis
Shares of biopharmaceutical company Cytokinetics were trading in the red in the after-hours market following news the Food and Drug Administration extended the prescription drug user fee act action date for the new drug application for aficamten.
The company is evaluating aficamten to treat patients with obstructive hypertrophic cardiomyopathy, a thickening of the heart muscle.
The FDA said it needed additional time to conduct a full review of the company's proposed risk evaluation and mitigation strategy, Cytokinetics said. No additional clinical data or studies have been requested by the FDA, the company also said.
After the bell, the company's shares were trading 13% lower, at $37.10. The stock closed Thursday's regular session at $42.92, basically flat on the day.
Year to date, the stock is down by over 33%.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 01, 2025 18:45 ET (22:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。